Published 2 months ago • loading... • Updated 2 months ago
R3 Bio Develops Headless Human Bodyoids for Organ Farming and Testing
The startup says the brain-free platforms could make testing more scalable and eventually provide a source of transplantable human tissues.
San Francisco-based biotech startup R3 Bio is developing genetically engineered 'bodyoids'—complete organ systems grown without brains—to replace laboratory animals in drug testing and preclinical research.
The pharmaceutical industry burns through millions of lab animals annually, yet nine out of ten drugs that pass animal trials still fail in humans. CEO Alice Gilman argued the sector needs systemic change.
R3 Bio utilizes induced pluripotent stem cells to grow these structures, with backing from investors including American billionaire Tim Draper and Singaporean investment fund Immortal Dragons to advance the technology.
While some reports suggested R3 Bio aims to create human clones, the company stated it "never made any statement regarding hypothetical" non-sentient human clones, emphasizing current focus on research platforms.
Beyond drug research, the company envisions these bodyoids eventually supplying transplantable organs, though significant regulatory and ethical questions remain regarding human-derived biological platforms and their future use.